ABCL-022: LOTIS-2 follow-up analysis: updated results from a phase 2 study of loncastuximab tesirine (lonca) in relapsed or refractory diffuse large B-cell lymphoma

Long-term follow-up data from the phase 2 LOTIS-2 study of patients with relapsed/refractory DLBCL receiving loncastuximab tesirine continued to demonstrate durable responses and no new safety concerns. The results, presented during the 2021 Annual Meeting of the Society of Hematologic Oncology, showed an overall response rate of 48.3%, complete response rate of 24.8%, and partial response rate of 23.4%.